Source:
www.podbean.co...
Welcome to a special 2 part episode of Allergytalk! On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab! In first part of a 2 part series, we will review the evidence behind the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUTMATCH) study that led to this FDA indication. In Part II, we will discuss important considerations in implementing omalizumab for food allergy in your practice.
Speakers:
Dr. Robert Wood, MD, the Julie and Neil Reinhard Professor of Pediatric Allergy and Immunology and Division Director at Johns Hopkins University School of Medicine and Primary Investigator of the OUTMATCH study.
Dr. Brian Vickery, MD, the Marcus Professor of Pediatric Immunology and Division Chief at Emory University and Children’s Healthcare of Atlanta. He was one of the site investigators of the OUTMATCH study.
Important Links:
Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, YovetichN, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Feb 25.
www.nejm.org/d...
Updated FDA label for omalizumab:
www.accessdata...
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose.
Dr. Wood has consulted for Genentech.
Dr. Vickery has consulted for Genentech and Novartis